Story

SK Biopharmaceuticals Stock Soars on $795 Million Epilepsy Drug Deal

ENTHMSVIIDZHZH-TWJAKOHI
Aug 26, 20261 min read
SK Biopharmaceuticals Stock Soars on $795 Million Epilepsy Drug Deal
Text size
Background

SK Biopharmaceuticals (326030.KS) shares jumped as much as 10.5% on Wednesday following the announcement of a significant global licensing deal to acquire an epilepsy treatment pipeline from Biohaven Bioscience Ireland. The agreement bolsters the company's portfolio in a core therapeutic area, signaling a substantial investment in future growth.

Deal Details

The deal gives SK Biopharmaceuticals worldwide rights to Biohaven's epilepsy drug candidate, Opakalim, along with a suite of related Kv7 activator compounds and the underlying discovery platform. The total potential value of the acquisition is up to $795 million.

SK Biopharmaceuticals will make an upfront payment of $400 million, structured as $350 million at closing and an additional $50 million one year later. The company described the transaction as one of its most significant pipeline investments to date, aimed at strengthening its position in the neurology market.

Sample IUX Markets – In-articleAd

Market Context and Performance

The market's positive reaction comes amid already strong commercial momentum for SK Biopharmaceuticals. The acquisition of an early-stage asset complements the company's proven commercial success with its existing epilepsy drug, Cenobamate.

According to a recent note from Heungkuk Securities, which reiterated a Buy rating on the stock, Cenobamate saw a 24% year-on-year increase in prescriptions in July. The company also reported strong second-quarter results, with consolidated revenue reaching 247.4 billion KRW, a 40.3% increase from the previous year. The broader KOSPI index was also up approximately 0.9% during Wednesday's trading session.

Read next

More on Stocks
Back to latest news

LATEST